Biofrontera AG (FRA:B8FK) ROCE %: 1.13% (As of Mar. 2026)

What is Biofrontera AG ROCE %?

Biofrontera AG FRA:B8FK 58 ROCE % is 1.13% as of Mar. 2026. GuruFocus rates FRA:B8FK with a GF Score™ of 58/100 and a GF Value™ of €2.29 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biofrontera AG's annualized ROCE % for the quarter that ended in Mar. 2026 was 1.13%.

Biofrontera AG (FRA:B8FK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biofrontera AG ROCE % Related Terms

Biofrontera AG ROCE % Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG ROCE % Chart

Biofrontera AG Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

73.81

-103.73

-9.39

-5.72

-7.09

Biofrontera AG Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-4.62	38.59	-9.81	-62.02	1.13

58GF Score

Biofrontera AG FRA:B8FK

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biofrontera AG ROCE % Calculation

Biofrontera AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-1.208	/	( ( (29.654 - 10.469)	+	(20.643 - 5.731) )	/ 2 )
	=	-1.208	/	( (19.185	+	14.912)	/ 2 )
	=	-1.208	/	17.0485
	=	-7.09 %

Biofrontera AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	0.188	/	( ( (20.643 - 5.731)	+	(22.737 - 4.481) )	/ 2 )
	=	0.188	/	( ( 14.912	+	18.256 )	/ 2 )
	=	0.188	/	16.584
	=	1.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 1.13% mean?

Biofrontera AG (FRA:B8FK) has a ROCE % of 1.13% as of Mar. 2026.

Is Biofrontera AG's ROCE % too high?

Biofrontera AG's current ROCE % is 1.13%. The Drug Manufacturers industry median ROCE % is 7.01. Biofrontera AG's value of 1.13% is 83.9% below this industry median. Overall, Biofrontera AG has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Biofrontera AG's ROCE % compare to ZTS and UTHR?

Biofrontera AG's ROCE % of 1.13% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Biofrontera AG's value of 1.13% is 83.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current ROCE % of 1.13% is 83.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current ROCE % is 1.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biofrontera AG stock overvalued right now?

Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.21 — trading 3.5% below its estimated fair value. The current ROCE % is 1.13% and 83.9% below the Drug Manufacturers industry median of 7.01. Biofrontera AG's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current ROCE % is 1.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.21 is trading 3.5% below its estimated GF Value™ of €2.29. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for FRA:B8FK:

ROCE %: 1.13%
GF Value™: €2.29 vs. price of €2.21 (3.5% below fair value)
GF Score™: 58/100 with 4 warning signs
Industry Position: 83.9% below the Drug Manufacturers median

No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM SHSE:688506 XPAR:IPN TSE:4507 TPE:6446

Other Exchanges 0DOL:UK B8FK:Germany

Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377

Website https://www.biofrontera.com

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.

58GF Score

Get the complete analysis for FRA:B8FK

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21

Price

€2.29

GF Value

View FRA:B8FK Analysis

See ROCE % data for all stocks →